Table 1.

Patient characteristics

		CTC enumeration/7.5 ml
Variable	Subcategory	< 5	< 50	≥ 50	P-value*
Clinical stage	Stage I–III (n = 8)	4 (50.0%)	4 (50.0%)	0	0.079
	Stage IV (n = 56)	13 (23.2%)	22 (39.3%)	21 (37.5%)
	Unknown (n = 2)	1 (50.0%)	0	1 (50.0%)
HER2 primary tumor	Amplified (n = 10)	3 (30.0%)	4 (40.0%)	3 (30.0%)	0.958
	Negative (n = 52)	14 (26.9%)	20 (38.5%)	18 (34.6%)
	Unknown (n = 4)	1 (25.0%)	2 (50.0%)	1 (25.0%)
HR primary tumor	Positive (n = 50)	11 (22.0%)	21 (42.0%)	18 (36.0%)	0.272
	Negative (n = 14)	6 (42.9%)	5 (35.7%)	3 (21.4%)
	Unknown (n = 2)	1 (50.0%)	0	1 (50.0%)

^*Chi-square test, patients with unknown clinical stage, HER2 or HR status were not included in statistical analysis.